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Summary 
In this randomized clinical trial comparing micafungin 100 mg with standard care antifungal 
prophylaxis (fluconazole, liposomal amphotericin B, or caspofungin) in high-risk liver 
transplant patients, micafungin 100 mg was non-inferior and had a better kidney safety 
profile. 
 
 
Abstract  
Background 
Invasive fungal infection (IFI) following liver transplantation is associated with significant 
morbidity and mortality. Antifungal prophylaxis is rational for liver transplant patients at high 
IFI risk. 
Methods 
In this open-label, non-inferiority study, patients were randomized 1:1 to receive 
intravenous micafungin 100 mg or center-specific standard care (fluconazole, liposomal 
amphotericin B, or caspofungin) post-transplant. The primary endpoint was clinical success 
(absence of a proven/probable IFI and no need for additional antifungals) at end of 
prophylaxis (EOP). Non-inferiority (10% margin) of micafungin versus standard care was 
assessed in the per protocol (PPS) and full analysis sets (FAS). Safety assessments included 
adverse events (AEs), liver and kidney function tests. 
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Results 
The FAS comprised 344 patients (172 micafungin; 172 standard care). Mean age was 51.2 
years; 48.0% had a Model for End-Stage Liver Disease (MELD) score ≥20. At EOP (mean 
treatment duration 17 days), clinical success was 98.6% for micafungin and 99.3% for 
standard care (Δ standard care–micafungin [95% CI]: 0.7% [-2.7, 4.4]) in the PPS and 
96.5% and 93.6%, respectively (-2.9% [-8.0, 1.9]), in the FAS. Incidences of drug-related 
AEs for micafungin and standard care were 11.6% and 16.3%, leading to discontinuation in 
6.4% and 11.6% of cases, respectively. At EOP, liver function tests were similar but 
creatinine clearance was higher in micafungin- versus standard care-treated patients. 
 
 
Conclusion 
Micafungin was non-inferior to standard care as antifungal prophylaxis in liver transplant 
patients at high IFI risk. AE profiles and liver function at EOP were similar although kidney 
function was better with micafungin.
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INTRODUCTION 
Liver transplant recipients are susceptible to invasive fungal infections (IFI), with infection 
rates of 8.4–17.7% reported in contemporary epidemiological studies [1-6]. Most IFI in solid 
organ transplant recipients belong to the genera Aspergillus and Candida [7, 8]. Candida 
species account for the majority (60–91%) of IFI in liver transplant patients [3, 5, 8, 9] with 
C. albicans and C. glabrata being most commonly observed [8, 10, 11].  
 
Risk factors associated with IFI in liver transplant recipients include pre- and post-
operative renal failure, re-transplantation, substantial intra-operative transfusion of cellular 
blood products [9], and high Model for End-Stage Liver Disease (MELD) score [2, 12, 13]. As 
IFI are associated with mortality rates of 25–90% [2, 4, 9, 14, 15], antifungal prophylaxis is 
a rational approach for liver transplant patients considered at high risk.  
 
Fluconazole and liposomal amphotericin B are US guideline-recommended options for 
antifungal prophylaxis in liver transplant recipients with multiple IFI risk factors [15-17]. 
However, some strains of Candida have shown resistance to fluconazole [17-19] and 
amphotericin B nephrotoxicity causes concern in renally impaired patients [20, 21]. The 
echinocandins have demonstrated broad efficacy against Candida species, have low toxicity, 
few drug–drug interactions and are established first-line treatments for invasive candidiasis 
[22-24]. Some centers give echinocandins as primary prophylaxis in liver transplant 
recipients [23] and European recommendations support their use in patients at high IFI risk 
[25]. The aim of TENPIN (Liver Transplant EuropeaN Study into the Prevention of Fungal 
InfectioN) was to demonstrate non-inferiority of the echinocandin micafungin versus center-
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specific standard care for IFI prevention in liver transplant recipients deemed at high risk of 
IFI.  
METHODS 
Patients and study design 
TENPIN was a Phase 3b, international, multicenter, randomized, open-label, parallel-group, 
non-inferiority, antifungal prophylaxis study in liver transplant recipients (ClinicalTrials.gov 
identifier: NCT01058174; clinicaltrialsregister.eu EudraCT number 2008-005214-49). 
Patients ≥18 years undergoing orthotopic whole or split liver allograft transplantation were 
eligible for inclusion based on the presence of at least one of the IFI risk factors described in 
Supplementary Appendix 1.1. Supplementary Appendix 1.2 details the exclusion criteria.  
 
Eligible patients were randomized 1:1 to receive, post-transplantation, either 
intravenous (i.v.) micafungin 100 mg/day (2.0 mg/kg/day if weight was <40 kg) or center-
specific standard care (a pre-defined regimen according to local protocol of either i.v. 
fluconazole 200–400 mg/day, i.v. liposomal amphotericin B 1–3 mg/kg/day, or i.v. 
caspofungin 70 mg single loading dose followed by 50 mg once daily). Patients were 
randomized at admission if they fulfilled the high IFI risk criteria or within 5 days post-
transplantation following intra- or post-operative events. Supplementary Appendix 
1.3/Figure S1 describes the randomization procedure.   
 
Prophylaxis lasted 21 days or until hospital discharge (whichever occurred first), or 
longer in patients with persistent risk factors. End of study (EOS) was 3 months post-
randomization and long-term follow-up (LTFU) was 6 months post-randomization. Patients 
who developed a proven or probable IFI during prophylaxis were discontinued from the 
study drug, treated with appropriate antifungal therapy, and required to remain in the study 
 at Biom
edische Bibliotheek on D
ecem
ber 28, 2014
http://cid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
6 
and complete all assessments. A proven or probable IFI, diagnosed by an investigator 
according to the EORTC/MSG definitions [26], was confirmed by an Independent Data 
Review Board (IDRB).  
 
The study protocol (ISN/Protocol 9463-EC-0001) was approved by the independent 
Ethics Committee or Institutional Review Board at each center and was conducted in 
accordance with the ethical principles that originate in the Declaration of Helsinki. Patients’ 
written informed consent was obtained prior to screening.  
 
The manuscript was written in accordance with the CONSORT statement for 
randomized controlled trials recommendations [27]. 
 
Outcomes  
Efficacy  
Fungal infection status was evaluated at baseline (methods provided in Supplementary 
Appendix 1.4), during prophylaxis, at end of prophylaxis (EOP), and at EOS by the 
investigator and blindly assessed by the IDRB. During prophylaxis, fungal infection status 
was assessed at a minimum of twice weekly, with assessments conducted at least 72 hours 
apart.  
 
The primary efficacy endpoint was clinical success (defined as a composite of 
absence of a proven or probable IFI and no initiation of antifungal treatment at EOP) 
assessed by the IDRB. Antifungal treatment was defined as either additional antifungal 
medication or increased study drug dose due to apparent inadequate efficacy. 
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Secondary pre-specified efficacy endpoints included: absence of a proven or 
probable IFI at EOP and EOS or EOS-Month 3 (i.e. more than post-randomization Day 76) as 
assessed by the IDRB and investigator; absence of initiation of antifungal therapy at EOP as 
assessed by the IDRB; time to proven or probable IFI from randomization according to the 
IDRB; fungal-free survival at EOS and end of LTFU according to the investigator. 
 
Safety 
Treatment-emergent adverse events (AEs) were recorded up to EOS, and serious 
AEs, including death, until 30 days after EOS. Overall mortality was considered a safety 
parameter. Routine laboratory assessments of biochemistry, hematology, and urinalysis 
were performed at baseline and throughout the study. Hepatic and renal function was 
assessed using standard laboratory biochemical tests. 
 
Statistical analysis 
Efficacy data were analyzed for the full analysis set (FAS), i.e. all randomized patients who 
received at least one dose of study medication and without proven or possible IFI at 
baseline (according to the IDRB) and the per protocol set (PPS), i.e. all FAS patients who 
completed the study without major protocol violations. The PPS was used as the primary 
analysis set and the FAS as the confirmatory analysis set for the primary efficacy endpoint 
and all secondary endpoints. The safety analysis set (SAF) included all randomized patients 
who received at least one dose of study medication.  
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The study sample size was calculated using a non-inferiority margin of 10% for the 
absolute difference in clinical success rates based on clinical judgment by an expert panel. 
Based on this non-inferiority margin, assuming a true success rate of 94% in the standard 
care group, 135 patients per group were necessary to demonstrate non-inferiority of 
micafungin versus standard care with a power of at least 90% using a one-sided type I risk 
error of 2.5%. Assuming that 80% of the randomized subjects were included in the PPS, 
169 patients were required to be randomized into each treatment group. Clinically, a non-
inferiority margin of 10% was also deemed applicable to the FAS.  
 
For the composite primary efficacy endpoint of clinical success, rates were compared 
between the standard care and micafungin groups at EOP and two-sided 95% confidence 
intervals (CI) for the difference in success rates were calculated using the Newcombe–
Wilson method. If the upper limit of the 95% CI for the difference in success rates was 
<10%, then the non-inferiority of micafungin to standard care was declared. The analysis 
assumed that the infection rate amongst the individual treatment regimens was 
homogeneous. The secondary efficacy endpoints of absence of proven or probable IFI (EOP, 
EOS and EOS-Month 3) and absence of antifungal therapy (EOP), and fungal-free survival 
were similarly analyzed, although as the study was powered for the primary endpoint, 
statistical non-inferiority was tested on this endpoint only.  
 
Time to proven or probable IFI was modeled using Cox regression, with covariates 
including baseline MELD score (≤29 or ≥30) and treatment group. Patients with no proven 
or probable IFI during prophylaxis were censored at the assessment visit. Non-parametric 
analysis was undertaken, Kaplan–Meier curves are provided, and the log-rank test utilized to 
 at Biom
edische Bibliotheek on D
ecem
ber 28, 2014
http://cid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
9 
compare treatment groups for the endpoints of time to proven or probable IFI and fungal-
free survival.  
 
Baseline characteristics (FAS) and safety variables (SAF) were summarized by 
descriptive statistics.  
 
In a post-hoc analysis to further explore renal safety, estimates of glomerular 
filtration rate (GFR) and creatinine clearance (CrCl) were derived for the SAF and also the 
SAF patients who did not require renal replacement therapy (RRT) at baseline, using the 4-
variable modification of diet in renal disease formula and Cockcroft–Gault formula, 
respectively. Differences in GFR and CrCl between treatment groups were compared at 
weekly time points using repeated measures analysis of variance (ANOVA) and at EOP by 
analysis of covariance (ANCOVA).  
 
Data analysis for this paper was generated using SAS/STAT® software, Version 9.3 
(2011), SAS Institute Inc, Cary, NC, USA. 
 
RESULTS 
Patients  
The study ran from 15 December 2009 to 03 May 2012 at 37 European centers. Figure 1 
shows participant flow. There were 45 micafungin-treated patients excluded from the study, 
mainly due to AEs (n = 27) or withdrawal of consent (n = 9) and 30 patients treated with 
standard care, mainly due to AEs (n = 23). Excluding MELD score, demographics and 
baseline characteristics were balanced between treatment groups (Table 1). The most 
common indications for transplantation were cirrhosis(67.5%) and hepatocellular carcinoma 
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(16.2%). Supplementary Appendix 2.1/Table S1 details the proportion of patients in each 
high-risk IFI category. The mean ± standard deviation duration of exposure was 16.7 ± 7.0 
days in the micafungin group and 17.1 ± 8.0 days in the standard care group. 
 
Efficacy  
Primary efficacy endpoint  
The clinical success rate of micafungin 100 mg was non-inferior to standard care at EOP as 
assessed by the IDRB in the primary analysis PPS: 98.6% (138/140) for micafungin and 
99.3% (136/137) for standard care (∆ standard care–micafungin [95% CI] 0.7% [-2.7, 
4.4]). This was confirmed in the FAS (Table 2). Of the 67 FAS patients excluded from PPS, 
67.1% were excluded because their EOP assessment was greater than 3 days after last 
treatment administration of study drug. 
 
Secondary efficacy endpoints in the full analysis set 
Micafungin was similar to standard care with regard to absence of proven or probable IFI at 
EOP and EOS, according to both IDRB and investigator assessments (Supplementary 
Appendix 2.2/Table S2). At EOP there were four (2.3%) IDRB-confirmed IFI in micafungin-
treated patients and eight (4.7%) in standard care-treated patients. At EOS there were 
three new infections in each group. Supplementary Appendix 2.3/Table S3 details the 
infecting species. With regard to absence of initiation of systemic antifungal treatment, the 
success rate of micafungin (98.8%) was also similar to standard care (95.9%) at EOP (∆ 
standard care–micafungin [95% CI] -3.0% [-7.2, 0.7]). 
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Cox regression modeling of time to proven or probable IFI gave a hazard ratio of 
0.72 (95% CI: 0.27, 1.90) indicating no significant difference between the groups. Non-
parametric analysis was consistent with this finding (log-rank test P = .498; Supplementary 
Appendix 2.4/Figure S2).  
 
Investigator-assessed fungal-free survival at EOS was 80.8% (126/156) and 83.2% 
(139/167) in the micafungin- and standard care-treated patients, respectively (∆ 2.5%; 95% 
CI: -5.9, 10.9) and at the end of LTFU was 78.1% (121/155) and 80.0% (132/165), 
respectively (∆ 1.9%; 95% CI: -7.0, 10.9). Kaplan–Meier analyses showed no significant 
difference in fungal-free survival at LTFU (log-rank P = .679; Figure 2). 
 
Safety 
Hepatic and renal functions 
There were no clinically relevant differences in hepatic function tests over time between 
micafungin- and standard care-treated patients (Supplementary Appendix 2.5/Figure S3).  
 
Serum creatinine and urea levels were lower in the micafungin group than standard 
care at most weekly time points and at EOP suggesting better renal function in these 
patients. Post-hoc analysis showed mean GFR and mean CrCl were higher for micafungin 
versus standard care at most time points during prophylaxis, although differences were not 
statistically significant (Supplementary Appendix 2.5, Figure S4). However, at EOP when 
data from all patients at any time were considered, mean GFR was significantly higher in 
micafungin- versus standard care-treated patients (P = .049), as was mean CrCl (P = .012). 
For patients not requiring RRT at baseline, significantly higher mean GFR (P = .033) and 
mean CrCl (P = .013) were observed for micafungin (n = 133) versus standard care (n = 
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142) at EOP, although not at weekly time points. Liposomal amphotericin B was associated 
with the lowest GFR and CrCl in standard care patients (Figures 3A and 3B). 
 
Treatment-emergent adverse events 
There were fewer AEs leading to study drug discontinuation in micafungin- than standard 
care-treated patients (6.4% vs 11.6%, respectively for treatment-related AEs; see 
Supplementary Appendix 2.6/Table S4). Table 3 shows AEs reported in >10% of patients in 
either treatment group. While a higher overall rate of graft rejections was reported for 
micafungin (19.1%) than standard care (11%), the rates of biopsy-confirmed treated acute 
rejection were similar at 9.8% and 8.1%, respectively. Most graft rejections were mild to 
moderate in severity, and the rate of severe rejections was the same in each group (2.3%). 
The most common treatment-related AEs are detailed in Supplementary Appendix 2.6.  
 
Deaths 
In the micafungin group 14 patients died during prophylaxis and 15 during LTFU and  in the 
standard care group 11 died during prophylaxis and 12 during LTFU). Two deaths (one in 
each group) were considered possibly study drug-related by the investigator. Cause of death 
was mostly septic shock with multi-organ failure and/or worsening of the underlying disease.  
 
 
DISCUSSION  
TENPIN is the first randomized controlled trial of an echinocandin as prophylaxis in liver 
transplant patients and the largest antifungal study in this patient population to date. 
Micafungin demonstrated a clinical success rate that was statistically non-inferior to standard 
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care, confirming that micafungin 100 mg is as effective as standard care for antifungal 
prophylaxis in liver transplant recipients at high-risk of IFI. In addition, micafungin had 
similar efficacy to standard care across all secondary efficacy outcomes assessed. Having an 
IDRB confirm the investigator’s decision based on a standard definition [26] strengthens the 
study results and was necessary given the definition of IFI can vary between centers and 
physicians.  
 
IFI rates of up to 17.7% [1-6] and 3-month cumulative IFI rates of approximately 
4% [10] have been reported in liver transplant recipients without risk factors. The overall 
low rate of IFI (≤2%) in our study provides evidence supporting antifungal prophylaxis in 
high-risk liver transplant recipients. Micafungin is indicated for prophylaxis against Candida 
infection in other high-risk patient groups [28, 29]; low rates of breakthrough IFI were 
observed for micafungin 50 mg (1.6%) and fluconazole (2.4%) in a trial comparing these 
agents in hematopoietic stem cell transplantation patients [30]. In that study [30], one 
patient on micafungin had a breakthrough Aspergillus infection (seven on fluconazole), while 
two patients on micafungin in the current study were infected with Aspergillus species and 
two on standard care (one each with fluconazole and liposomal amphotericin B). 
 
The overall safety profile of micafungin was comparable to that of standard care, 
with a low incidence of hepatic and renal AEs. The pattern of liver function tests was similar 
between micafungin and standard care, however renal function with micafungin may be 
better than with established standard care regimens, such as liposomal amphotericin B. This 
is consistent with a prophylaxis study in high-risk liver transplant recipients where 
micafungin was similarly efficacious to amphotericin B lipid complex, with lower early renal 
dysfunction and no additional risk of hepatic dysfunction [21]. In our study more graft 
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rejection episodes were reported in micafungin patients than standard care. However, 
further investigation found similar rates of biopsy-confirmed treated acute rejection – an 
objective measure of rejection – and there was no evidence that micafungin was different to 
standard care in this regard.  
 
Alternatives to fluconazole and liposomal amphotericin B, the current guideline-
recommended options for antifungal prophylaxis in liver transplant recipients, are needed. 
Candida species such as C. glabrata and C. krusei are less susceptible, or even resistant in 
the case of fluconazole, to these agents [17-19, 31]. Drug–drug interactions with 
fluconazole complicate dosing with the immunosuppressants ciclosporin, tacrolimus, and 
sirolimus [32]. Fluconazole requires dose adjustment in patients receiving RRT, as the 
procedure results in a significant clearance of fluconazole, which varies depending on the 
technique used [33, 34]. Although nephrotoxicity risk is reduced with liposomal amphotericin 
B compared with amphotericin B deoxycholate [15, 17], it may still limit it’s use, [20, 35] 
especially in recipients with renal dysfunction. 
 
Echinocandins may be useful alternatives for simplifying antifungal prophylaxis in 
liver transplant, exhibiting excellent fungicidal activity against Candida species, with low 
minimum inhibitory concentrations against the majority of isolates [36, 37]. Resistance to 
echinocandins is a relatively rare event [37-39]. However, cases of resistance due to 
therapy-acquired FKS mutations have been reported [37, 38], and evidence of increasing 
resistance among strains of C. glabrata has emerged [40]. The probability of resistance may 
increase as echinocandin use escalates, and this needs to be considered when employing 
these agents as primary prophylaxis with prolonged exposure. As echinocandins do not 
interact with the P450 cytochrome or P-glycoprotein systems they have a low potential for 
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drug–drug interactions [36, 37]. However, caspofungin [41] but not micafungin [42-45] 
does interact with ciclosporin and tacrolimus and micafungin interacts with sirolimus [28]. 
 
This study’s main limitations include those inherently associated with open-label 
trials, such as potential bias which can, for example, lead to greater withdrawal of consent 
in one treatment arm. This was observed in this study as nine patients on micafungin 
withdrew consent compared with none on standard care. In addition, standard care therapy 
was decided as per local guidelines and standard care dosing was not uniform (although 
within a pre-agreed range and consistent with each center), which may have impacted 
results. As the choice of standard care was center-specific, and therefore could be based on 
local epidemiology or other clinical considerations relevant to the local patient population, 
this could be considered as a positive bias in favor of standard care in the TENPIN clinical 
trial setting. For the post-hoc safety analysis on renal function it was only possible to 
exclude patients who had RRT at baseline because information on whether they received 
RRT during prophylaxis or thereafter was not collected. In addition, it was not possible to 
adjust for known nephrotoxic concomitant medications.  
 
In summary, micafungin was demonstrated non-inferior to standard care for 
antifungal prophylaxis in liver transplant patients at high risk of IFI, with a similar overall 
safety profile but associated with better renal function throughout prophylaxis than standard 
care. Micafungin therefore provides an additional prophylactic option, especially in patients 
with a high risk of infection by species resistant to current standard care, patients at risk of 
drug–drug interactions, or patients with renal impairment or receiving RRT.  
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Figure legends 
Figure 1. Disposition of patients 
 
*All randomized patients with at least 1 dose of study drug. 
†All randomized patients with at least 1 dose of study drug and without an invasive fungal 
infection at baseline. 
‡All patients who completed the study without major protocol deviations or violations. 
§Patients from the full analysis set who discontinued; for every patient, only the primary 
reason for discontinuation was collected. 
 
Figure 2. Fungal-free survival in micafungin and standard care treatment groups 
during long-term follow-up (full analysis set) 
Abbreviation: IFI, invasive fungal infection 
 
Figure 3. A, Mean glomerular filtration rate and B, Mean creatinine clearance in 
patients not requiring renal replacement therapy, according to specific study 
drug 
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Table 1. Demographic and baseline characteristics  
 
Micafungin 
100 mg 
(n = 172) 
Standard care 
 
(n = 172 ) 
Total 
 
(n = 344) 
Male sex, n (%) 118 (68.6) 114 (66.3) 232 (67.4) 
Mean ± SD  age, years 51.9 ± 10.5 50.5 ± 11.8  51.2 ± 11.2 
Mean ± SD body mass index (kg/m2) 25.8 ± 4.3 25.3 ± 5.0 25.6 ± 4.6 
Ethnicity, n (%) 
White 
Black  
Asian 
Other 
 
165 (95.9) 
  3 ( 1.7) 
  3 ( 1.7) 
  1 ( 0.6) 
 
159 (92.4) 
  7 ( 4.1) 
  5 ( 2.9) 
  1 ( 0.6) 
 
324 (94.2) 
 10 ( 2.9) 
  8 ( 2.3) 
  2 ( 0.6) 
Region, n (%) 
West Europe 
East Europe 
South Europe 
 
 71 (41.3) 
 17 (9.9) 
 84 (48.8) 
 
 72 (41.9) 
 14 (8.1) 
 86 (50.0) 
 
143 (41.6) 
 31 (9.0) 
170 (49.4) 
Mean ± SD MELD score  19.9 ± 10.0 21.1 ± 10.0 20.5 ± 10.0 
MELD score, n (%) 
<20  
20–29 
≥30 
98 (57.0) 
43 (25.0) 
31 (18.0) 
81 (47.1) 
54 (31.4) 
37 (21.5) 
 
179 (52.0) 
 97 (28.2) 
 68 (19.8) 
CMV mismatch (recipient/donor), n (%)
Negative/negative 
Negative/positive 
Positive/negative 
Positive/positive 
26 (15.2) 
27 (15.8) 
34 (19.9) 
70 (40.9) 
20 (11.8) 
23 (13.5) 
46 (27.1) 
67 (39.4) 
 
46 (13.5) 
50 (14.7) 
80 (23.5) 
137 (40.2) 
Abbreviations: CMV, cytomegalovirus; MELD, Model for End-Stage Liver Disease; SD, 
standard deviation. 
Note: Percentages are based on all patients with available data in the respective treatment 
regimen. For CMV mismatch, the number of patients with available data is equal to the 
number of patients with both assessments available.  
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Table 2. Clinical success rate for micafungin and standard care at the end of the 
prophylaxis period and as assessed by the Independent Data Review Board (per 
protocol and full analysis sets) 
Per protocol set 
(primary analysis) 
 
Micafungin
n (%) 
(n = 140) 
Standard care
n (%) 
(n = 137) 
Difference, % 
(95% CI) 
Standard care – 
micafungin 
Clinical success 138 (98.6)  136 (99.3)  0.7 (-2.7, 4.4) 
No clinical success 2 (1.4) 1 (0.7)
Invasive fungal 
infectiona 
2 (1.4) 1 (0.7)
Antifungal treatmenta 0 0
No assessments 
available 
0 0  
Full analysis set 
(confirmatory 
analysis) 
Micafungin
  n (%) 
(n = 172) 
Standard care
n (%) 
(n = 172) 
Difference, % 
(95% CI) 
Standard care – 
micafungin 
Clinical success  166 (96.5) 161 (93.6) -2.9 (-8.0, 1.9)
No clinical success 6 (3.5) 11 (6.4)
Invasive fungal 
infectiona 
4 (2.3) 
 
8 (4.7)
 
Antifungal treatmenta 2 (1.2) 7 (4.1)
No assessments 
available 
2 (1.2) 3 (1.7)  
Abbreviation: CI, confidence interval.  
a One patient may have proven or probable invasive fungal infection and may have started 
antifungal treatment.
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Table 3. Treatment-emergent adverse events in more than 10% of patients in 
the micafungin treatment or standard care group (safety analysis set) 
 
 
 
 
 
 
 
 
 
 
 
 
Treatment-emergent adverse events, n 
(%) 
Micafungin
(n = 173) 
Standard 
care 
(n = 172) 
Abdominal pain 
Diarrhea 
Pleural effusion 
Anemia 
Liver transplant rejection (clinical) 
Pyrexia 
Hypertension 
Cholestasis 
21 (12.1)
19 (11.0) 
26 (15.0) 
20 (11.6) 
29 (16.8) 
16 (9.2) 
26 (15.0) 
12 (6.9) 
15 (8.7)
19 (11.0) 
38 (22.1) 
23 (13.4) 
14 (8.1) 
19 (11.0) 
18 (10.5) 
19 (11.0) 
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